Transdermal drug-delivery company Medherant said yesterday it raised $5.1 million (GBP £3.8 million) in a funding round as it looks to move its drug-delivering ibuprofen Tepi Patch into clinical development early next year.
The funding round was led by majority shareholder Mercia Technologies and joined by existing shareholders and new private investors, the Coventry, U.K.-based company said.
Read the whole story on our sister site, Drug Delivery Business
The post Medherant raises $5m to move transdermal ibuprofen patch to clinical trials appeared first on MassDevice.
from MassDevice http://ift.tt/2nVk0Ju
Cap comentari:
Publica un comentari a l'entrada